<?xml version="1.0" encoding="UTF-8"?>
<p>The regulation and rules of access to compassionate use programmes varies between National government authorities across EU Member States. In the United Kingdom, the early access to medicines scheme (EAMS) gives patients with life‐threatening or debilitating conditions access to innovative medicines without marketing authorization, but for which there is a clear medical need. A two‐stage evaluation process initially considers promising innovative medicine (PIM) designation before an EAMS scientific opinion. Also in the United Kingdom, the potential supply of unlicensed medicinal products (Specials) may be considered by the Medicines and Healthcare Products Regulatory Agency (MHRA) for the importation of medicines that have marketing authorization status from countries outside the United Kingdom and European Union.</p>
